14 February 2024 in Science Translational Medicine
ATM is a key mediator of radiation response, and pharmacological inhibition of ATM is a rational strategy to radiosensitize tumors. AZD1390 is a brain-penetrant ATM inhibitor and a potent radiosensitizer. This study evaluated the spectrum of radiosensitizing effects and the impact of TP53 mutation status in a panel of IDH1 wild-type (WT) glioblastoma (GBM) patient-derived xenografts (PDXs). AZD1390 suppressed radiation-induced ATM signaling, abrogated G 0 -G 1 arrest, and promoted a proapoptotic response specifically in p53-mutant GBM in vitro. In a preclinical trial using 10 orthotopic GBM models, AZD1390/RT afforded benefit in a cohort of TP53 -mutant tumors but not in TP53 -WT PDXs. In mechanistic studies, increased endogenous DNA damage and constitutive ATM signaling were observed in TP53 -mutant, but not in TP53 -WT, PDXs. In plasmid-based reporter assays, GBM43 ( TP53 -mutant) showed elevated DNA repair capacity compared with that in GBM14 (p53-WT), whereas treatment with AZD1390 specifically suppressed homologous recombination (HR) efficiency, in part, by stalling RAD51 unloading. Furthermore, overexpression of a dominant-negative TP53 (p53DD) construct resulted in enhanced basal ATM signaling, HR activity, and AZD1390-mediated radiosensitization in GBM14. Analyzing RNA-seq data from TCGA showed up-regulation of HR pathway genes in TP53 -mutant human GBM. Together, our results imply that increased basal ATM signaling and enhanced dependence on HR represent a unique susceptibility of TP53 -mutant cells to ATM inhibitor–mediated radiosensitization.
14 October 2025 in Oncogene
1 January 2026 in Theranostics
Glioblastoma (GBM) is an “immune desert” tumor, characterized by a highly immunosuppressive tumor microenvironment (TME), which leads to immune evasion and resistance to immunotherapies. The stimulator of interferon (IFN) genes (STING) signaling pathway serves as a central hub for priming anti-tumor immunity by driving the production of type I IFNs. Thus, STING activation has shown promise for overcoming immunosuppressive TME and inhibiting tumor malignancies. Accumulating preclinical evidence shows that STING agonists exert strong antitumor effects across multiple GBM models. However, the diverse and complex roles of the STING signaling pathway in reshaping the GBM microenvironment have not been fully summarized or elucidated. This review provides an overview of the mechanisms underlying STING dysregulation and the regulatory effect of STING activation on immune cell infiltration, priming, and function. Moreover, STING agonist monotherapies, and their combination regimens or delivery via innovative platforms for GBM treatment, are critically appraised, highlighting their implications for future clinical translation.